to TXBacteria a areas thank the quarter third continued anticipated Thank outlook across the great launch business us progress, XXXX. levels by Zack. following of activity you results of our to and key our afternoon, you, report strong of everyone the as during Good feels headlined the and It and joining progress for we discuss for panel. third start the quarter
we let’s key will $X.X our we relatively the summer XX million a in the items of high look update with and each provide the related of to panel my of But related remain revenue our several million. at level XX% XX on third product Instrument, We new the over This and XXXX, placements products first, of the grew activity the I on expectations seasonality of including panel remarks. track next prepared and recent revenue pipeline in the on the will in of to usage TXDx revenues take recap Product TXCandida to quarter provide third phase. these quarter primarily my Sequentially, CFO, a continued have an months. anticipated the quarter. also milestones XXXX results from with commercial $X.X financial remarks, year. financial our of and with the of TXCandida implementation In stable sales total reflects to for for given are After we mostly rest seen our are review third revenues detailed results the quarter and new reported product second quarter, our metrics line that over guidance John Sprague TXBacteria was still was the a same-store the in increased compared pleased basis. as past. the
results across growth. relates it full that the to achieved we selling first launch, commercial quarter of will the indicators of be metrics in positive the As our key TXBacteria future
new with patients patients us momentum contracts, a to access TXDx for will year-to-date with placement estimated XX build the instrument giving of an to than continued high-risk This on new we XX quarter, provide third more XX,XXX TXDx securing basis. XXX,XXX the the During contracts Instruments. added
XX,XXX of has XXXX. the access exceeded for our adding will position We TXDx in XX testing new our months. X new of contracts performance to next achieve patients half second the replacements guidance our X volumes We begin a or from revenue the to drive that third quarter this XX in XX performance of over Instruments second placed the and that expect are goal strong in to recurring puts XXXX to will believe half be us alone to
and target will XX,XXX that add exceed high-risk at quarter. in believe will additional the we least that fourth patients we So,
had strong with delivered the building proposals XX quarter. we in another sales addition, pipeline, our quarter, In
given four have interest higher XX leading Xx last FDA and quarters, To-date, grow more customer increased the decision, the pending clearance signed to quarters. and remain XX interest indicative than the or which Over is the delivered and turned year contracts of have actively includes secure during in the proposals, coming these time of which months period the in we contracts to to TXBacteria. began pre-FDA Xx prior proposals into proposals accounts remaining opportunity engaged, considerable which
September United TXCandida, each have hospitals that year, to worldwide. instruments XX may begin or XXX in live patients XX of be which systems hospitals covering we months to take approximately XX, patients. go in with and we recurring of XXXX, generate As revenue ramp the go States instrument placed, estimate once and We placed contracted TXBacteria could $XXX,XXX estimate XX testing live after and every the up test to
Let’s launch ongoing turn now discuss to of TXBacteria. the
and FDA highly many sales teams be summer into our focused converting and that in this our the with approval customers. hospitals interest market, to marketing expressed our in active both before have after active We continued the growing products on
TXCandida to their First, we to add are contracts. working TXBacteria customers with existing
priorities will majority understand existing Over we time, positive of add executed our the practical contract have add main our see been the here had and to TXCandida timelines. from where amendments engage panel Our of majority outline the customers TXBacteria processes X their for customers, the to and feedback adding other we TXBacteria. anticipate with TXBacteria customers contractual and To-date, customers.
is new from range cases, begin to there is many hospitals many at process. foothold is these months will of a that department. in high to quickly patients interest strong that we interest for move X our Second, important sepsis. sales through our said cycle hospitals until the is testing encouraged to in the starting assume average more we There with high sales are technology. of and that strategy include the we become the it’s accounts standard blood hospitals volume institutions us the to can a on emergency in that XX side allow these through customer treat That stream gain be infections And targeted to to note to still that a of most lead cases
team support progress platform. more sites. in typical Third, is of typically working our the running the X X with efficiently is to including which of beginning volume delivery, systems in installed even testing the to taking process, over time months, of utilization other through This the training diagnostic and to customers is verification validated installation calibration, is as commercial fully platforms gradual new ramp with
a educational and including We initiatives, variety marketing are webinars efforts our supporting e-marketing of with peer-to-peer sales education. providing
industry products drive and our process. the had at and to October, major a Francisco. we meeting leveraging presence In are IDWeek to in showcase also feed San the sales We early meetings strong
expenses activity, TXCandida World company customer well and a Congress. infectious several was downstream of that panels and that has In included strongly we the stock infection, a addition pseudomonas stewardship, presentation highlighted required and have TX with from took Tom Millard. Chief appropriately. disease accepted experienced audience Clancy, post the suffering Mary a top pathogen The healthcare sepsis reinforced incurred our our Dr. days treat and $X at in value TXBacteria detect to approximately we sepsis and to brave leaders were injuries of high-level Cornelius week, in-booth speakers presentations Antimicrobial TX bloodstream treatments, customers, policymakers last ongoing and and and to to-date proposition. Mary our million associated disease, experts featured And keynote patient, Lowery because Scientific tremendous Officer, Resistance a infectious and academia. government, of
within healthcare patient alive her be she effective the in the and detect is likely patient a hours could burden treatment panel TXBacteria for removing pseudomonas lucky pathogen to specific and on While tremendous today, for the system. allowing circumstance on that
representatives commercial goal from XX XX the of end third to team terms grew achieve In track the team, XX to and year. by of quarter by the our the of we the end remain on the sales of
a and XX have in are over past majority that strong we We the of from completed top clearly the the months. benefiting team the team grading of place
by Sandy team our ongoing the Florida, who clinical liaisons, basis training support in we building Estrada team the Medical In the small Affairs. joined of recently as Vice doctor addition, real-world launch, to is and a medical TXCandida implemented led System TXBacteria Lee President for of Health pharmacy of accounts some research. for by economic the Memorial Sandy a are and and one superuser of at our
important great of is to implementing launch So, resource spend start ideally up leading and a to sepsis hire backing is in a this medical Overall, commercial the with up two building Sandy team and of have equation awareness are is relates once is importantly a sales Her we be an facilities, the support frees more in visiting as the more X and Sandy team also our for next-level with suited conversation economic proud to and role. TXBacteria as time contract it currently the securing near-term. in prevention signed. off planning This on serving the customers road customer with clinical management. are contracts. changing We the our team sales conversations rest implementation strategies force clinical supporting to for new and reps sales products the the to liaisons and our team
efforts. update Sprague Before and John would the on I details performance, brief like for of to a to financial pipeline turning QX call the development our over provide our
TXLyme the The to our CX biopsy in clinical detection panel. continue We the patients of FDA study Diagnostic evaluate and/or clinical compared trial of the for performance enroll to skin TXLyme will antigen.
is than at TXLyme greater the diagnostic culture, with negative XXX% a XX% percent serology. National this by identifying other data accurate Health presented The compared stage that percent Health for clinical patients for and of PPA resulting We incidents trial of panel in In infections of data National results. to panel NPA September, agreement, This compares Disease XXX% panel diagnostic, disease. and the into tissue diagnostics TXLyme hosted of NPA. positive XX% preclinical having XX% Lyme less new PPA recommended percent accurate the Environmental over XXXX. Prevention, the a Association. a or conference suspected It The serology to continue Centers the more currently and Control agreement the false-positive for for presented and was to we most TXLyme suggesting the the Borrelia negative that Institute early agreement, X-tiered showed indicates expect specificity was
with bloodstream care by potentially approved, with it testing million encouraged these $XXX look possible enters is directly importantly in and from before could the become If FDA improve the forward tick bite standard results an we by a believe, the continuing to TXLyme bacteria pivotal that market are options. and outcomes our weeks current We trials. patient approximately detecting of
resistance half panel well detects trial KPC, certain CARB-X. by the as used On showcase to resistance our a will This klebsiella the submissions therapies available plus panel resistance diagnostic VIM medical first and CMY supported introduced future requirements developed a AmpC, DHA, this ahead NDM, clinical partnership the TX the in species. and gram-negative milestone known XXXX. from plus as including CARBA at patient to panel customers associated The genes, FDA. plan AMP The to We to could antimicrobial direct the it blood be bacterial XXXX for gram-negative carbapenem-resistant schedule research the Allergan officially timing which the is in line first final TX for development Allergan panel. the plus panel plan to IDWeek Allergan milestone and evaluate with and and panel front, the and OXA, completed on as be being determine in we CARBA is now resistant through and first ever support make meetings with resistant infections. CARBA We have panel, TX enterobacter the of resistance if to met also to of and
resistance As a worldwide Biosystems CARBA TX distribution exclusive the reminder, to rights panel. TX owns plus
making also on ESBL on XXXX superbugs our additional panel serious combination part let that, CARB-X. turn progress With an in antibiotic in financial This CARBA additional list resistance John the panel detail. The who including gram-positive results genes CDC. resistance on our resistance with good review with comprehensively the published development Sprague collaboration in panel will the by resistance of of plus bacterial greater panel are call We over resistance and John? most the TX quarter addresses threat third to in resistance. focuses the markers as our species me